This page is intended for Australian registered Health Care Professionals only. Visit www.theramex.com.au for consumer information.

Register your interest here for Bijuva Starter Packs,
a Representative visit and Medical Information

Fields marked with an * are mandatory 

By submitting this request, I confirm I am a registered health care professional. I agree for Theramex to contact me by email with information about women’s health therapies. Theramex will not disclose your personal information to anyone other than contractors who provide services to us or unless compelled or permitted by law to do so. To view our full privacy policy please refer to our global website www.theramex.com. 

PBS Information: Bijuva is not listed on the PBS.


PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING. Product Information is available from Medical Information: 1800 THERAMEX (1800 843 726)

Bijuva® Minimum Product Information: This product contains a boxed warning, please visit the product information online or via Medical Information for full details. Bijuva® 1 mg of estradiol (as hemihydrate) and 100 mg of progesterone. Indication:  Continuous combined hormone replacement therapy (MHT/HRT) for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses. Contraindications: Known, past or suspected breast cancer; known or suspected estrogen-dependent malignant tumours; undiagnosed genital bleeding; untreated endometrial hyperplasia; venous thromboembolism; known thrombophilic disorders; active or recent arterial thromboembolic disease; acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal; Porphyria; known hypersensitivity to the active substances or to any of the excipients. Precautions: Appraisal of the risks and benefits should be undertaken at least annually. Before initiating, a complete personal and family medical history should be taken. Refer to full product information for conditions that require supervision during treatment. Immediate withdrawal of therapy should be applied in the following situations: Jaundice or deterioration in liver function, significant increase in blood pressure, new onset of migraine-type headache, pregnancy. Cautions: endometrial hyperplasia and carcinoma, breast cancer, ovarian cancer, venous thromboembolism, coronary artery disease (CAD), ischemic stroke, thyroid hormone levels, use in renal impairment, use in elderly, pediatric use. Interactions: The metabolism of estrogens and progestogens may be increased by use of drug-metabolizing enzymes, specifically cytochrome P450 enzymes, such as anticonvulsants, rifampicin, rifabutin, nevirapine, efavirenz, and griseofulvin, St John’s Wort, Ritonavir, nelfinavir. Adverse Events: breast tenderness, headache, nausea, pelvic pain, vaginal haemorrhage and vaginal discharge (see PI for others) Dosage: Take one capsule each evening with food. Sponsored in Australia by Theramex Australia Pty Ltd, ABN 37 623 186 845, 60 Margaret Street, Sydney, NSW 2000. www.theramex.com.au Based on the PI last updated 3 May 2022. Abbreviations: ccMHT; continuous combined menopausal hormone therapy. Date of preparation: May 2022. 007322